Given the correlation between IDO and HLA-G in different human tumors, anti-HLA-G antibodies may be used in combination with these inhibitors, such as Indoximod and Epacadosat, to further increase their effect on the rescue of anti-tumor immune response. Here, IDO1 is linked to neoplasm.